Protagonist Therapeutics, Inc. PTGX
Updated: 10 Sep 2026
No signal published yet
We already track Protagonist Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Protagonist Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Protagonist Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In September 2026, Protagonist Therapeutics announced a $300 million share repurchase program following the U.S. FDA approval of MIMRYLO (rusfertide) for polycythemia vera in August 2026. The approval triggered milestone payments and commercial royalty rights under its partnership agreements. The company also presented updates on its clinical pipeline and strategic progress at investor conferences in September 2026.
What Firelda Watch includes for Protagonist Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Protagonist Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Protagonist Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more